Neurohk s.r.o.
- Address
- lock Available on a paid plan
Musculoskeletal Diseases
Neurohk s.r.o. is conducting studies that target pain and movement disorders, aiming to improve symptom relief and functional outcomes for patients with chronic conditions.
- chronic non-specific low back pain
- cervical dystonia
- musculoskeletal pain management
The research focuses on evaluating new therapeutic approaches to reduce pain intensity and enhance quality of life for individuals whose standard treatments have been insufficient.
Nervous System Diseases
The site’s neurology program investigates treatments for progressive neurological disorders, seeking to slow disease progression and preserve motor and cognitive function.
- relapsing‑remitting multiple sclerosis
- early Parkinson's disease
- migraine prevention and acute therapy
By testing innovative agents, researchers aim to provide safer, more effective options for patients living with these chronic nervous‑system diseases.
Mental Disorders
Clinical work at Neurohk s.r.o. addresses neuropsychiatric symptoms that significantly impact daily living, with a focus on developing therapies that lessen severe behavioral disturbances.
- agitation associated with Alzheimer’s disease
- Alzheimer’s disease psychosis
- Lewy body dementia psychosis
- hallucinations and delusions in dementia
The trials evaluate safety and efficacy of novel compounds to improve behavioral outcomes and reduce caregiver burden in affected individuals.
Psychological Phenomena
Research into core psychological symptoms accompanies the site’s broader neuro‑psychiatric agenda, aiming to refine treatment strategies for complex mental presentations.
- agitation in dementia
- hallucinations
- delusions
- mood and cognitive disturbances
Findings from these studies are intended to guide clinicians toward more precise, patient‑centered interventions for challenging psychological phenomena.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Acadia Pharmaceuticals Inc.3active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Acadia Pharmaceuticals Inc.4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neurohk s.r.o.
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) | Acadia Pharmaceuticals Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acp-204 Tartrate | 4 | Unknown | 2024-07-02 | 2026-05-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.